skip to main content

AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.(Report)

Fulgham, Pat F. ; Rukstalis, Daniel B. ; Turkbey, Ismail Baris ; Rubenstein, Jonathan N. ; Taneja, Samir ; Carroll, Peter R. ; Pinto, Peter A. ; Bjurlin, Marc A. ; Eggener, Scott

The Journal of Urology, 2017, Vol.198(4), p.832 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.(Report)
  • Autor: Fulgham, Pat F. ; Rukstalis, Daniel B. ; Turkbey, Ismail Baris ; Rubenstein, Jonathan N. ; Taneja, Samir ; Carroll, Peter R. ; Pinto, Peter A. ; Bjurlin, Marc A. ; Eggener, Scott
  • Assuntos: Cancer Diagnosis ; Prostate Cancer ; Magnetic Resonance Imaging ; Cancer Screening ; Prostate Specific Antigen
  • É parte de: The Journal of Urology, 2017, Vol.198(4), p.832
  • Descrição: To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.juro.2017.04.101 Byline: Pat F. Fulgham [pfulgham@airmail.net] (a,*), Daniel B. Rukstalis (b), Ismail Baris Turkbey (c), Jonathan N. Rubenstein (d), Samir Taneja (e), Peter R. Carroll (f), Peter A. Pinto (c), Marc A. Bjurlin (e), Scott Eggener (g) Key Words prostatic neoplasms; magnetic resonance imaging; image-guided biopsy; early detection of cancer Purpose We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer. Materials and Methods A panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus. Results At this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer. Conclusions Although it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving. Abbreviations and Acronyms DCE-MRI, dynamic contrast enhanced MRI; ERC, endorectal coil; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; PI-RADS[TM], Prostate Imaging Reporting and Data System; PSA, prostate specific antigen; W, weighted Author Affiliation: (a) Texas Health Presbyterian Hospital of Dallas, Dallas, Texas (b) Wake Forest Baptist Medical Center, Winston-Salem, North Carolina (c) National Cancer Institute, National Institutes of Health, Bethesda, Maryland (d) Chesapeake Urology Associates, Baltimore, Maryland (e) NYU Langone Medical Center, New York, New York (f) University of California San Francisco, San Francisco, Calfornia (g) The University of Chicago Medical Center, Chicago, Illinois * Correspondence: Texas Health Presbyterian Dallas, Dallas, Texas 75231 Article History: Accepted 3 May 2017 (footnote) The complete unabridged version of this policy statement is available at http://jurology.com/(http://jurology.com/). (footnote) No direct or indirect commercial incentive associated with publishing this article. (footnote) The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.